Another day, another promise of imminent riches from a biotech clinical trial! This time it’s from Ray Blanco, who has made many such promises in his ads, and the pitch is all about a “bio switch” that has the potential to “end diabetes, plus heart & kidney disease (with a twice-a-day pill).” What more could […]
Articles
- Most Relevant
- Most Recent
This is really disappointing. All this time I’ve been under the impression that your friendly neighborhood Stock Gumshoe and his terrifically handsome likeness were all the “female Viagra” the world needed … but apparently some pharmaceutical companies disagree, and have been trying to develop a drug along those lines. At least, that’s the pitch from […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
Today I thought we’d take a look at an Elliott Gue teaser for a stock that he thinks will be taken over by, of all people, the Rockefellers. Or maybe it’s The Rockefellers. He’s selling his Energy Strategist newsletter … and you’ll see why this teaser specifically appealed to me in a minute. Here’s a […]
That’s a subtle headline, right? I already issued a bit of a “brain dump” for the Irregulars this week, on Wednesday instead of Friday, but I couldn’t resist taking a little look at this latest teaser pitch from Patrick Cox for his Transformational Technology Alert. Quite a few readers have been asking about it, and […]
“Tulane University Confirms Medical Breakthrough: “Tiny Biotech Unveils ‘Single Shot’ Cure for Heart Disease “The news could go public any day… and this small San Diego-based company will instantly dominate a $305 BILLION market. “Investors who act now could book gains of 9,275%… “ Now THAT’S what I want to hear — looking at gold […]
I saved this teaser pitch to cover for you, dear Irregulars… and I confess that it’s mostly because covering a company this tiny and illiquid for our larger group of free readers feels a little bit irresponsible. Even if I say cynical or skeptical things about a stock, talking to thousands of my closest friends […]
Thanks so much to the new folks who’ve joined us as Irregulars this week — we’re midway through our annual charitable membership drive, and it’s looking pretty good… I’m hoping we can get our totals up to last year’s numbers, and we’re almost halfway there with a donation pile of close to $6,000 now. That’s […]
“When this controversial law takes effect on October 1, 2011… folks who act now could get ‘hedge fund rich’” That’s how Zachary Scheidt is launching his new service, called Hedge Fund Strategist from Taipan, a publisher in the Baltimore Agora-plex (Taipan is currently in the process of renaming itself “Insiders Strategy Group,” just to keep […]
Ah, another one from the Motley Fool! Like mother’s milk, it nourishes the Gumshoe so to pore through a ponderous Fool tome in search of clues to great stocks. Today, we’re blessed with a teaser letter for the Hidden Gems newsletter, with the letter coming from Bill Mann, who runs that newsletter in partnership with […]
I’ll warn you up front: if you’ve been sailing the seas with us here on the good ship Gumshoe for more than a couple years, you’ve already seen this one. But Benjamin Shepherd at the Global Investment Strategist is now saying that it’s “The One Stock You Must Buy in 2014” so I thought we […]
More from Navellier for you today — I covered several of his growth picks last week in response to one of his Blue Chip Growth teaser campaigns, and now I’m getting to a few more. If you want to see the intro to this series, and the first few picks, just check out that original […]
So… what’s going in in the Real Money Portfolio this week, as we close up shop and get ready for a bit of time with family and friends? I do have one buy to share with you today, I decided to pick up some shares of the stock that I wrote to you about a […]
A fantastic market last week, a terrible market this week… it’s time, once again for another episode of “Turn Off CNBC and Have Some Perspective!” I won’t go into a long screed about long-term investing here, but I thought I’d just share one of my favorite charts — I see someone post something like this […]
These are my notes and instant reactions from a presentation at the Value Investing Congress, the notes below might contain errors, paraphrases, incorrect quotes, or misinterpretations. Sahm Adrangi is a relatively new guy to the value investing world, Kerrisdale Capital is about five years old and (unlike many) they share their research — particularly on […]
Qualcomm (QCOM) is now back to having a 4% yield… which was pretty hard to resist for me this week. The stock is in the headlines every day of late and is well off its highs, of course, following the high-profile pursuit by Broadcom (AVGO) that was called off this week, but not all the […]
Well, if you see a teaser pitch for Canadian Edge you know, at least, that the stocks being teased are, well, Canadian. So that helps us out — it means we can hopefully put just a couple litres of fuel into our Thinkolateur and we ought to be well on our way to some nice, […]
I haven’t yet gotten to a few of my largest holdings in our Annual Review, so that’s where I’ll begin today — with the insurance conglomerates Berkshire Hathaway (BRK-B), Markel (MKL), and Fairfax Financial (FFH.TO, FRFHF), as well as the somewhat related names Fairfax India (FIH-U.TO, FFXDF) and Boston Omaha (BOMN). I should be clear […]
Thanks for your kind wishes (and patience) as I took a couple weeks off with my family — we had a wonderful and relaxing getaway in a few of the jewels of the Rocky Mountains as we toured through some northern national parks, most of them blessedly devoid of cell phone service or wifi, but […]
There’s been a big push on in recent days for subscriptions to some of Doug Casey’s newsletters, with the ad that I’ve been most recently asked about being for a “combo deal” that gets you subscriptions to Casey International Speculator and their flagship Casey Report (for a “discount” price, naturally, though it renews at a […]
EV >>>—Vehicles-October-02-17–&-Beyond——->How do we get there? >>>—Water, Air, Earth, Fire——-> #Inspired by Dad, Arch1, Griffin, HendrixNuzzles, #ZKSS, Robert Friedland, Matt Bohlsen o ”LOVE is all that matters. Love IS all there is…” ~ Dad, Hours after flight! 😉 o ”Sums it up. just like a coffee maker. Clean out used grounds and repeat as needed. Espresso […]
Sometimes literary gimmicks backfire. In May 2015, we premiered “Cisco, Chang & Charlie” (sans Oxford comma) as a James Joycean brooding on the letter C, third letter of the alphabet, in three iterations. At the time, three stocks whose names begin with C were vying for attention and prompting questions from readers. The original plan […]
I spent the day on Tuesday at the Delivering Alpha conference, which is hosted by CNBC and Institutional Investor — it’s not the kind of confab that includes “secret” or special ideas that you can’t hear about elsewhere (it’s hosted by CNBC, after all, and they broadcast from the conference all day), but it’s an […]
This is the third time I’ve bought an IPO on its first day of trading, and the second time I’ve bought exposure to a SPAC over the past year — hopefully it will work out as well as the others. I saw Chamath Palihapitiya speak at the Delivering Alpha conference on Tuesday, along with Starwood’s […]
Glenn Newberry in an earlier post today was asking whether Benlysta from GlaxoSmithKline (GSK), being trialled for lupus nephritis, poses any threat to Aurinia (AUPH). Benlysta is a monoclonal antibody that binds to and inhibits BAFF (B-cell activating factor). A company called Anthera (ANTH) is trialling blisibimod, an oral agent that does the same thing. […]
Remember Ernie Tremblay’s pitch about a “tiny South Texas lab” that was about to cure every disease using its revolutionary CD19 Cancer Vaccine technology, and ignite a bidding war following its fantastical release of exciting information on June 23? Well, it’s back. Not the stock, that’s still languishing around where it was before Tremblay got […]
We are always, always tempted by anything that promises hope to sufferers of Alzheimer’s Disease and their families… not just because we’re humanitarians and love people, and have seen the pain of this disease, but because Alzheimer’s treatment is by far the largest (mostly) unmet medical need in the US, both because the population of […]
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues and trends. He does not typically write about specific investment opportunities, but has agreed to our trading restrictions… as with all of our authors, […]
I don’t spend a lot of time writing to you about my mutual fund and other diversified holdings in my portfolio, many of which are effectively indexed to the S&P 500, but I wrote to you a little over a year ago about the “better mousetrap” fund from DoubleLine that tries to provide a “double […]
Things will be a little quiet here at Stock Gumshoe for the next week or so — I’m off to do my big fundraising ride for Dana-Farber tomorrow, and will then be taking several days off to recuperate next week and spend time with family… I’ll be back with the Friday File next week, but […]
This week I’m breaking up the Friday File into two parts — there was a clamor of request to cover the latest “Code of Life” teaser pitch from Michael Robinson, so I did that for you in a separate piece today… And I’ve also got some comments about recent earnings updates and some other news […]
We’ve got a good backlog of teaser pitches to get to, as usual, but this one filtered to the top for our attention today — it’s an ad from David Fessler for his Oxford Resource Explorer newsletter (currently $79), and the ad seems mostly to have gotten folks’ attention because of a link from one […]
Motley Fool Canada launched a new dividend-focused newsletter service called Dividend Investor Canada earlier this year, and they’re now promoting it using a promise that they’re finding retail’s “next generation of ‘hidden millionaires.” And, of course, the bait that they dangle to entice you to subscribe is a report with some “secret” stocks that they […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
I’ve got a soft spot in my heart (or maybe my head, depends who you ask) for the Motley Fool’s old “Superbrand” ads — one of the very first teaser pitches I covered when I started this website in the Spring of 2007 was the Gardner brothers’ teaser for the “New American Superbrand”. That ad […]
This Friday File article was originally released to the Irregulars on June 16, we have now opened it up for anyone to read in hopes of answering some questions that continue to roll in about the latest Biotech Insider Alert ads. The text below has not been updated or revised, though I and other readers […]
Over time, I will try to collect past posts on these topics and collect them here. I’ll try to get the original posters and dates, although some are missing in this first post. JIN SHIN JYUTSU POSTS BY REBS (formerly Roger) Roger – At 87 I do Qigong, 8 brocades, Yang 10, 24, 48, 42, […]
These kinds of ads always include some huge numbers that sound really, really impressive… here’s a little bit of the intro from the latest ad for Briton Ryle’s The Wealth Advisory: “*Jim T. collected $23,500 last month from ‘backdooring’ Google’s Account *Ron J. ‘backdoored’ $15,804 from Facebook’s Account *Aaron K. pocketed $6,817 last month from […]
I’ve been asked a few questions about the gold stocks in my portfolio, so I thought I’d run through a few of them today and provide whatever updated opinion and assessment I can for you — including a few portfolio adjustments I’ve just made. And, as an added bonus, I’m adding one new gold stock […]
[ed. note: Michael Jorrin, who I call Doc Gumshoe, is a longtime medical writer (not a doctor) who writes for us about medicine and health a couple times a month. He has agreed to our trading and disclosure restrictions, but does not generally write directly about investment ideas. His ideas, thoughts and words are his […]